37,40 €
1,16 % gestern
L&S, 30. Oktober, 22:54 Uhr
ISIN
US22663K1079
Symbol
CRNX
Berichte

Crinetics Pharmaceuticals Inc Aktie News

Neutral
GlobeNewsWire
8 Tage alt
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effects Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor e...
Neutral
GlobeNewsWire
20 Tage alt
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an aggregate of 54,475 restricted stock unit (“RSU”) awards to 20 new non-executive employees,...
Neutral
GlobeNewsWire
24 Tage alt
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Positiv
The Motley Fool
etwa ein Monat alt
Crinetics Pharmaceuticals (CRNX 27.92%) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpriced. The U.S. Food and Drug Administration (FDA) approval on Sept.
Positiv
Seeking Alpha
etwa ein Monat alt
Crinetics Pharmaceuticals received FDA approval for PALSONIFY, the first daily oral therapy for adults with Acromegaly, addressing a large unmet need. The company has submitted a Marketing Authorization Application for paltusotine in the EU, with a CHMP opinion expected in the first half of 2026. Expansion opportunities include a phase 3 study for carcinoid syndrome and two phase 3 trials for a...
Positiv
Investors Business Daily
etwa ein Monat alt
Shares of Crinetics Pharmaceuticals surged Friday after the Food and Drug Administration approved the company's acromegaly drug, Palsonify.
Neutral
Seeking Alpha
etwa ein Monat alt
Crinetics Pharmaceuticals, Inc. - Special Call Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, President, CEO & Director Dana Pizzuti - Chief Medical & Development Officer Isabel Kalofonos - Chief Commercial Officer Tobin Schilke - Chief Financial Officer Alan Krasner - Chief Endocrinologist Conference Call Participants Joshua Schimmer - Can...
Neutral
GlobeNewsWire
etwa ein Monat alt
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid, durable, and consistent biochemical control and reduced symptom burden Launch of lead product PALSONIFY marks a pivotal milestone for ...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen